Related Experiment Video
Updated: Aug 14, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation under-utilization in atrial fibrillation patients is responsible for a large proportion of strokes
Banafsheh Shakibajahromi1, Scott E Kasner1, Catherine Schmitt1
1University of Pennsylvania, Department of Neurology.
Insights
Underutilization of anticoagulation (AC) in atrial fibrillation (AF) patients significantly increases the risk of stroke requiring endovascular thrombectomy (EVT). Most AF strokes needing EVT are potentially preventable with adequate AC therapy.
Area of Science:
- Neurology
- Cardiology
- Public Health
Background:
- Atrial fibrillation (AF) is a major cause of large strokes, often necessitating endovascular thrombectomy (EVT).
- Underutilization of anticoagulation (AC) therapy is a frequent reason for AF-related strokes.
- Identifying preventable strokes is crucial for improving patient outcomes.
Purpose of the Study:
- To compare antithrombotic medication use in AF patients who did and did not undergo EVT.
- To determine if AC underutilization disproportionately leads to strokes requiring EVT.
- To quantify the number of EVTs that could potentially be prevented by adequate AC.
Main Methods:
- Retrospective cohort study of acute ischemic stroke patients (2016-2021).
- Patients categorized by AF presence and EVT status.
- Comparison of pre-admission antithrombotic medications and reasons for AC non-use.
Main Results:
- Of 644 AF patients, 213 underwent EVT.
- EVT patients were more likely to be off antithrombotics (34% vs 24%) or sub-therapeutically anticoagulated (83% vs 63% on warfarin).
- Only 44% of AF-EVT patients were on AC, with 31% adequately anticoagulated; only 8% had contraindications, and 94% were discharged on AC.
Conclusions:
- Lack of antithrombotic therapy in AF patients disproportionately contributes to strokes requiring EVT.
- A small minority of AF patients have contraindications to AC.
- Adequate anticoagulation can prevent a significant number of strokes requiring EVT.
Objectives:
Atrial fibrillation (AF) is responsible for 30-50% of large strokes requiring endovascular thrombectomy (EVT). Anticoagulation (AC) underutilization is a common source of AF-related stroke. We compared antithrombotic medications among stroke patients with AF that did or did not undergo EVT to determine if AC underutilization disproportionately results in strokes requiring EVT, while quantifying the proportion of likely preventable thrombectomies.
Methods:
This retrospective single-center cohort included consecutive patients admitted with acute ischemic stroke between 2016 and 2021. Patients were categorized based on the presence of AF, and pre-admission antithrombotic medications were compared between those who underwent EVT and those who didn't. The reason for not being on AC was abstracted from the medical record, and patients were categorized as either AC eligible or AC contraindicated.
Results:
Of 3092 acute ischemic stroke patients, 644 had a history of AF, 213 of whom underwent EVT. Patients who required EVT were more likely to not be taking any antithrombotics prior to admission (34% vs 24%, p=0.007) or have subtherapeutic INR on admission if taking warfarin (83% vs 63%; p = 0.046). Among the AF-EVT patients, 44% were taking AC, and only 31% were adequately anticoagulated. Only 8% of AF-EVT patients who were not on pre-admission AC had a clear contraindication, and 94% were ultimately discharged on AC.
Conclusions:
Lack of antithrombotic therapy in AF patients disproportionately contributes to strokes requiring EVT. A small minority of AF patients have contraindications to AC, so adequate anticoagulation can prevent a remarkable number of strokes requiring EVT.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Clot Retraction and Fibrinolysis

